Home  |  Contact

Cellosaurus NK-92MI (CVCL_3755)

[Text version]

Cell line name NK-92MI
Synonyms NK-92 MI; NK-92 mi; NK92-MI; NK92MI; NK-92 transfected with MFG-hIL2
Accession CVCL_3755
Resource Identification Initiative To cite this cell line use: NK-92MI (RRID:CVCL_3755)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Characteristics: No longer dependent on IL2.
Microsatellite instability: Stable (MSS) (Sanger).
Transfected with: HGNC; 6001; IL2.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
Derived from sampling site: Peripheral blood.
Disease Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2142 (NK-92)
Children:
CVCL_JX95 (NK-92MIhCD16)CVCL_JX96 (NK-92MIhCD64)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP

Markers:
AmelogeninX,Y
CSF1PO11,12
D5S81812,13
D7S82010,11
D13S3179,12
D16S53911,12
TH016,9.3
TPOX8
vWA16,18

Run an STR similarity search on this cell line
Publications

PubMed=10365666; DOI=10.1089/10430349950018030
Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T., Klingemann H.-G.
Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Hum. Gene Ther. 10:1359-1373(1999)

Patent=US8034332
Klingemann H.-G.
Interleukin-secreting natural killer cell lines and methods of use.
Patent number US8034332, 11-Oct-2011

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-2408
ATCC; PTA-6671 - Discontinued
BCRC; 60438
KCB; KCB 200677YJ
Cell line databases/resources CCLE; NK92MI_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3111C0002000000065
CCRID; 3131C0001000200022
Cell_Model_Passport; SIDM01201
Cosmic-CLP; 1330981
GDSC; 1330981
LINCS_LDP; LCL-1127
Ontologies CLO; CLO_0008178
Gene expression databases GEO; GSM1670278
Other Wikidata; Q54930658